NVAX Jun 2024 13.500 put
| Previous Close | 0.5500 |
| Open | 0.5400 |
| Bid | 0.4600 |
| Ask | 0.5300 |
| Strike | 13.50 |
| Expire Date | 2024-06-28 |
| Day's Range | 0.3700 - 0.6000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 216 |
Investor's Business DailyThe FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Novavax stock seesawed on June 6 after the FDA assigned an April review date for its Covid vaccine. Is NVAX stock a buy right now?
ZacksNovavax (NVAX) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Novavax (NVAX) closed at $14.06, indicating a +1.99% shift from the previous trading day.
PR NewswireNovavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has submitted an amendment to its Emergency Use Authorization to the U.S. Food and Drug Administration (FDA) for its updated JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission is in line with guidance from the U.S. FDA, European Medicines Agency (EMA) and the World Health Organization (WHO) to target the JN.1 lineage this fall.1-3
